Dasatinib‐induced chylothorax: An unusual presentation of a common adverse event—A case report with literature review
<p></p><div> <p>Tyrosine kinase inhibitors (TKIs) are the key agents for treating CML and BCR–ABL<sup>+</sup> B-ALL. Dasatinib is a potent second-generation TKI. Here, we have discussed the case of a 51-year-old gentleman diagnosed with B-myeloid mixed-phenotype a...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , |
| Published: |
2023
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|